"Forty-Third Medical Associates Absolute Clinical Research"
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Beach, James L
NCT04020341 / 2018-001801-98: A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)

Recruiting
3
2055
Europe, US, RoW
Gepotidacin, Placebo matching nitrofurantoin, Nitrofurantoin, Placebo matching gepotidacin
GlaxoSmithKline
Urinary Tract Infections
12/22
12/22
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Checkmark Multimodal Circulating Tumor DNA (ctDNA) Blood-Based Colorectal Cancer (CRC) Screening Test Demonstrates Clinically Meaningful Sensitivity Across Multiple Clinical Parameters
Recruiting
N/A
10000
US
Guardant Health, Inc., Health Decisions
Colorectal Cancer
01/22
01/24
Rodriguez, Lucia
NCT04518410: ACTIV-2: A Study for Outpatients With COVID-19

Checkmark Efficacy and safety data from ACTIV-2 trial in combination with BRII-198 for COVID-19
Recruiting
2/3
8797
Canada, US, RoW
bamlanivimab, LY3819253, Placebo (IV), BRII-196/BRII-198, AZD7442 (IV), AZD8895 + AZD1061, AZD7442 (IM), SNG001, Camostat, FOY-305, camostat mesilate, camostat mesylate, Placebo (IM), Placebo (Inhaled solution), Placebo (oral tablet), BMS-986414 + BMS-986413, C135-LS + C144-LS, Placebo (SC injections), SAB-185 (3,840 Units/kg), Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (Tc bovine-derived), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, REGN10933 + REGN10987, REGN-COV2
National Institute of Allergy and Infectious Diseases (NIAID), Eli Lilly and Company, AIDS Clinical Trials Group, Brii Biosciences Limited, AstraZeneca, Sagent Pharmaceuticals, Synairgen Research Ltd., Bristol-Myers Squibb, SAb Biotherapeutics, Inc.
Coronavirus, Covid19
12/23
12/23
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Checkmark Multimodal Circulating Tumor DNA (ctDNA) Blood-Based Colorectal Cancer (CRC) Screening Test Demonstrates Clinically Meaningful Sensitivity Across Multiple Clinical Parameters
Recruiting
N/A
10000
US
Guardant Health, Inc., Health Decisions
Colorectal Cancer
01/22
01/24

Download Options